ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 68 filers reported holding ONCOMED PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 30.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $0 | – | 380 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 380 | 0.0% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 380 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $1,000 | 0.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $1,000 | -50.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $2,000 | 0.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,000 | +100.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,000 | -66.7% | 380 | 0.0% | 0.00% | -50.0% |
| Q1 2017 | $3,000 | 0.0% | 380 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $3,000 | -25.0% | 380 | 0.0% | 0.00% | -33.3% |
| Q3 2016 | $4,000 | -20.0% | 380 | 0.0% | 0.00% | -25.0% |
| Q2 2016 | $5,000 | +25.0% | 380 | 0.0% | 0.00% | +33.3% |
| Q1 2016 | $4,000 | -55.6% | 380 | 0.0% | 0.00% | -57.1% |
| Q4 2015 | $9,000 | +50.0% | 380 | 0.0% | 0.01% | +40.0% |
| Q3 2015 | $6,000 | -33.3% | 380 | 0.0% | 0.01% | -16.7% |
| Q2 2015 | $9,000 | – | 380 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,042,989 | $8,571,000 | 0.75% |
| NEXTHERA CAPITAL LP | 634,715 | $1,346,000 | 0.26% |
| Endurant Capital Management LP | 219,114 | $465,000 | 0.21% |
| Birchview Capital, LP | 118,689 | $252,000 | 0.16% |
| Perceptive Advisors | 2,620,897 | $5,556,000 | 0.15% |
| Alambic Investment Management, L.P. | 53,972 | $114,000 | 0.09% |
| Sofinnova Investments, Inc. | 395,744 | $839,000 | 0.08% |
| Kazazian Asset Management, LLC | 31,475 | $67,000 | 0.06% |
| Broadfin Capital, LLC | 200,000 | $424,000 | 0.06% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 96,639 | $205,000 | 0.02% |